AB Science has announced an operating loss of 15.9 million euros for 2022, up 15.4% on the previous year, and a cash position of 7.3 million euros at December 31, 2022.

To this cash position must be added the contribution of 11.5 million euros from the capital increase completed in April 2023, 7.1 million from the CIR for 2020 and 2021, and six million from the second tranche of financing with the EIB drawn down in January 2023.

The pharmaceutical laboratory's operating revenues, exclusively made up of sales linked to the operation of a drug in veterinary medicine, amounted to 958,000 euros in 2022, compared with 1.61 million a year earlier.

Copyright (c) 2023 CercleFinance.com. All rights reserved.